Intercepting Cancer When DNA Surveillance Fails
About this episode
Marina Udier discusses Nouscom's approach to developing cancer vaccines that train the immune system to detect and eliminate cancer cells early.
Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few options beyond constant screening and, in some cases, preventive surgery. Nouscom is trying to change that by training the immune system to spot and destroy cancer cells before tumors ever form. We spoke to Marina Udier, CEO of Nouscom, about the company’s experimental cancer vaccines, how they work, and the broader potential for the company’s off‑the‑shelf cancer therapies.
People in this episode
Guest: Marina Udier
Mentioned in this episode
Organizations: Nouscom, Lynch syndrome
More episodes of The Bio Report
- Slowing Disability in MS
- Tuning, Rather than Blocking, Immunity in IBD
- Targeting Psychosis in Alzheimer’s Disease
- A Class Action Suits Moves RICO from Mobsters to Medicine
- Outsmarting Resistance with Rhythm
- Editing Away Autoimmunity at the HLA Source
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.